FY2025 · ended Dec 31, 2025 · Revenue $129.42M, +29.9% YoY · Filed Mar 4, 2026
Niagen Bioscience, Inc. (NAGE) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $129.4 million and net income of $17.4 million. As of Jun 30, 2026 it held $66.7 million in cash and investments and $2.3 million in total debt.
Revenue (TTM)
$129.08M
+11.0% vs year-ago TTM
Net income (TTM)
$15.99M
-9.8% vs year-ago TTM
Operating cash flow (TTM)
$5.95M
-72.0% vs year-ago TTM
Free cash flow
$-21.18M
+4.7% vs prior year
EPS (TTM)
$0.19
-11.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
80.08M
+3.0% vs prior year
Net cash
$64.41M
as of Jun 30, 2026
Operating margin
8.2%
FY 2026
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- NAGE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1386570
- Former names
- ChromaDex Corp. (until Mar 10, 2025); CODY RESOURCES, INC. (until Jun 24, 2008)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $129.4M | $99.6M | $83.6M | $72.0M | $67.4M |
| Operating income | $16.3M | $7.7M | -$5.6M | -$18.6M | -$27.1M |
| Net income | $17.4M | $8.6M | -$4.9M | -$16.5M | -$27.1M |
| Diluted EPS | $0.20 | $0.11 | -$0.07 | -$0.24 | -$0.40 |
| Operating cash flow | $13.5M | $12.1M | $7.1M | -$15.1M | -$24.2M |
| Total assets | $106.4M | $68.3M | $55.0M | $54.1M | $57.8M |
| Total liabilities | $29.9M | $22.2M | $26.5M | $25.4M | $26.1M |
| Stockholders' equity | $76.5M | $46.1M | $28.5M | $28.7M | $31.7M |
| Cash and investments | $64.8M | $44.7M | $27.3M | $20.4M | $28.2M |
| Total debt | $2.8M | $2.6M | $3.3M | $4.2M | $4.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 6, 2026 | May 6, 2026 |
All 981 Niagen Bioscience, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.